FDA-2018-P-1846

Requests that the FDA immediately require the addition of boxed warnings, warning, preacautions, and highlights of prescribing information to the product label for all selective serotonin reuptake inhibitor and serotonin-norepinephrine reuptake inhibitor products, including branded and generic formulations to warn of serious and severe risks.